A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

被引：25
作者：
Thondam, S. K. [1 ]
Cuthbertson, D. J. [1 ]
Aditya, B. S. [1 ]
MacFarlane, I. A. [1 ]
Wilding, J. P. [1 ]
Daousi, C. [1 ]
机构：
[1] Univ Liverpool, Dept Obes & Endocrinol, Aintree Univ Hosp NHS Fdn Trust Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
CLINICAL ENDOCRINOLOGY | 2012年 / 77卷 / 04期
关键词：
FOOD-INTAKE; WEIGHT; HUMANS; DAMAGE;
D O I：
10.1111/j.1365-2265.2012.04368.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [41] Glucagon-Like Peptide-1 Agonists
    Stanton, Eloise W.
    Manasyan, Artur
    Banerjee, Rakhi
    Hong, Kurt
    Koesters, Emma
    Daar, David A.
    ANNALS OF PLASTIC SURGERY, 2025, 94 (01) : 121 - 127
  • [42] Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake
    Navarro, M
    deFonseca, FR
    Alvarez, EA
    Chowen, JA
    Zueco, JA
    Gomez, R
    Eng, J
    Blazquez, E
    JOURNAL OF NEUROCHEMISTRY, 1996, 67 (05) : 1982 - 1991
  • [43] Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study
    Ahern, T.
    Tobin, A. -M.
    Corrigan, M.
    Hogan, A.
    Sweeney, C.
    Kirby, B.
    O'Shea, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (11) : 1440 - 1443
  • [44] A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1 and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice
    Gault, Victor A.
    Bhat, Vikas K.
    Irwin, Nigel
    Flatt, Peter R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (49) : 35581 - 35591
  • [45] Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
    Wysham, Carol H.
    Pilon, Dominic
    Ingham, Mike
    Lafeuille, Marie-Helene
    Emond, Bruno
    Kamstra, Rhiannon
    Pfeifer, Michael
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1125 - 1133
  • [46] Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
    Inoue, Kana
    Maeda, Norikazu
    Fujishima, Yuya
    Fukuda, Shiro
    Nagao, Hirofumi
    Yamaoka, Masaya
    Hirata, Ayumu
    Nishizawa, Hitoshi
    Funahashi, Tohru
    Shimomura, Iichiro
    DIABETOLOGY & METABOLIC SYNDROME, 2014, 6
  • [47] The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
    Chuong, Vicky
    Farokhnia, Mehdi
    Khom, Sophia
    Pince, Claire L.
    Elvig, Sophie K.
    Vlkolinsky, Roman
    Marchette, Renata C. N.
    Koob, George F.
    Roberto, Marisa
    Vendruscolo, Leandro F.
    Leggio, Lorenzo
    JCI INSIGHT, 2023, 8 (12)
  • [48] Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis
    Geloneze, Bruno
    de Lima-Junior, Jose Carlos
    Velloso, Licio A.
    DRUGS, 2017, 77 (05) : 493 - 503
  • [49] Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
    Zheng, Zhikai
    Zong, Yao
    Ma, Yiyang
    Tian, Yucheng
    Pang, Yidan
    Zhang, Changqing
    Gao, Junjie
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [50] Actions of glucagon-like peptide-1 receptor ligands in the gut
    Holst, Jens Juul
    Andersen, Daniel Bjorklund
    Grunddal, Kaare Villum
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 727 - 742
12345